Modality
mRNA
MOA
MALT1i
Target
KRASG12C
Pathway
Lipid Met
Obesity
Development Pipeline
Preclinical
Aug 2018
→ Jan 2027
PreclinicalCurrent
NCT08669572
1,679 pts·Obesity
2018-08→2026-02·Recruiting
NCT05900378
1,232 pts·Obesity
2018-08→2027-01·Active
2,911 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-02-181mo agoInterim· Obesity
2027-01-119mo awayInterim· Obesity
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027
Preclinical
Recruit…
Preclinical
Active
Catalysts
Interim
2026-02-18 · 1mo ago
Obesity
Interim
2027-01-11 · 9mo away
Obesity
RecruitingActive|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08669572 | Preclinical | Obesity | Recruiting | 1679 | EASI-75 |
| NCT05900378 | Preclinical | Obesity | Active | 1232 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| JNJ-2735 | Johnson & Johnson | Phase 2/3 | Cl18.2 | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| RHH-974 | Roche | Preclinical | JAK1 | |
| NVS-3297 | Novartis | Preclinical | CDK2 | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| BMY-4586 | Bristol-Myers Squibb | Preclinical | KRASG12C | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| AMG-4531 | Amgen | Phase 2/3 | KRASG12C | |
| REG-8074 | Regeneron | Phase 2/3 | KRASG12C |